GlassScriptPhysician profile
Velma A Bacak
NPI 1104819234
$802.89
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $32.71 · 2021: $137 · 2022: $242 · 2023: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $131.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $206.42 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $184.07 | 2021-2023 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $101.39 | 2021-2022 | |
| Almatica Pharma LLC | $52.22 | 2022 | |
| Janssen Pharmaceuticals, INC | $38.86 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.89 | 2021 | |
| Vanda Pharmaceuticals INC. | $31.40 | 2022 | |
| Alkermes, INC. | $30.24 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $24.54 | 2019 | |
| Abbvie INC. | $21.85 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.46 | 2022 | |
| Corium, LLC | $17.77 | 2022 | |
| Eisai INC. | $14.49 | 2020 | |
| Adlon Therapeutics L.P. | $12.22 | 2021 | |
| Neurocrine Biosciences, INC. | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Velma Bacak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.